当前位置: X-MOL 学术Lancet Respir. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
NELSON trial: reduced lung-cancer mortality with volume CT screening.
The Lancet Respiratory Medicine ( IF 76.2 ) Pub Date : 2020-02-06 , DOI: 10.1016/s2213-2600(20)30059-x
Quintina Dawson

Globally, lung cancer is the leading cause of cancer-related death, accounting for an estimated 2·09 million cases yearly, which results in 1·76 million deaths. The high mortality rate is due to many patients not being diagnosed until they have advanced-stage disease, at which point treatment options are limited and prognosis is poor. Therefore, early detection and intervention is crucial for better outcome and survival.

中文翻译:

NELSON试验:通过体积CT筛查降低肺癌死亡率。

在全球范围内,肺癌是与癌症相关的死亡的主要原因,每年估计约有2·09百万例,导致1·76百万例死亡。高死亡率是由于许多患者直到他们患有晚期疾病才被诊断出来,在这一点上,治疗选择有限且预后不良。因此,早期发现和干预对于改善预后和生存至关重要。
更新日期:2020-03-03
down
wechat
bug